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ABSTRACT
Compared to normal kidney, renal clear cell carcinomas (ccRCC) contain increased 
numbers of interstitial, non-hematopoietic CD133+cells that express stem cell 
markers and exhibit low rates of proliferation. These cells fail to form tumors upon 
transplantation but support tumor formation by differentiated malignant cells. We 
hypothesized that killing of ccRCC CD133+ (RCCCD133+) cells by cytotoxic agents might 
be enhanced by inducing them to divide. Since tumor necrosis factor-alpha (TNF), 
signalling through TNFR2, induces proliferation of malignant renal tubular epithelial 
cells, we investigated whether TNFR2 might similarly affect RCCCD133+cells. We compared 
treating organ cultures of ccRCC vs adjacent nontumour kidney (NK) and RCCCD133+ vs 
NK CD133+ (NKCD133+) cell cultures with wild-type TNF (wtTNF) or TNF muteins selective 
for TNFR1 (R1TNF) or TNFR2 (R2TNF). In organ cultures, R2TNF increased expression 
of TNFR2 and promoted cell cycle entry of both RCCCD133+ and NKCD133+ but effects were 
greater in RCCCD133+. In contrast, R1TNF increased TNFR1 expression and promoted cell 
death. Importantly, cyclophosphamide triggered much more cell death in RCCCD133+ and 
NKCD133+cells pre-treated with R2TNF as compared to untreated controls. We conclude 
that selective engagement of TNFR2 by TNF can drives RCCCD133+ proliferation and 
thereby increase sensitivity to cell cycle-dependent cytotoxicity.
INTRODUCTION
Renal cell carcinoma (RCC) accounts for 85% 
of renal cancers, of which clear cell RCC (ccRCC) is 
the most prevalent form [1–5]. RCC responds poorly to 
cytotoxic drugs. Although, the prognosis for patients with 
this disease has recently improved due to earlier detection 
of RCC and expansion of treatment possibilities such 
as mTor inhibitors and VEGFR-targeted tyrosine kinase 
inhibitors [1], these treatments rarely yield complete 
responses. T-cell checkpoint inhibitors show promise 
but are not standard of care at the time of writing. Thus, 
RCC is still a tumor with poor clinical outcome and 
identification of additional cellular treatment targets is of 
utmost importance for improving prognosis.
CD133 is a pentaspan transmembrane glycoprotein 
(Prominin-1), whose specific functions are still unclear. 
It was initially identified as a specific marker for 
hematopoietic stem cells [6, 7] but more recently it has 
been proposed to be a stem/progenitor marker in a variety 
of adult tissues including normal human kidney and RCC 
[8–22]. However, the specificity of CD133 as a marker for 
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stem/progenitor cells is a matter of debate (reviewed by 
Wu and Wu et al., [23], as it has been found on various 
differentiated adult epithelial cells, including renal tubular 
cells [10, 24–28]. Although CD133+ cells from several 
human tumors exhibit xenotransplantation potential in 
severe combined immunodeficiency (SCID) mice [8, 18, 19, 
29], CD133+ cells from human RCC tissue (RCCCD133+cells) 
[27] fail to form tumors when transplanted independently 
in SCID mice but instead potentiate tumor engraftment 
when co-transplanted with CD133- RCC cells [29]. Higher 
numbers of CD133+cells in RCC tissue has been correlated 
with increasing tumor grade [22] and was associated with 
a favourable prognosis in some studies [27, 30] but not 
others [31]. While it is unclear whether RCCCD133+cells 
are true tumor stem cells and their prognostic significance 
is uncertain, their ability to promote tumor formation by 
CD133- RCC cells may contribute to the resistance of these 
tumors to conventional chemotherapy so that elimination of 
this population may improve outcomes.
Tumor necrosis factor-alpha (TNF) is a cytokine 
secreted by RCC with a number of tumor promoting 
properties [32] and inhibition or blockade of TNF has 
shown clinical benefit in some patients with RCC [33–
35]. This seems paradoxical as TNF was first identified 
as a cytokine that induced hemorrhagic necrosis of 
experimental tumors in mice [36]. We have shown that 
TNF can induce both cell death and proliferation in ccRCC 
cells in organ culture [37], and the relative expression and 
ligation of TNF receptor (TNFR) 1 and TNFR2 may be a 
key determinant of which pathways dominate. Specifically, 
ligation of TNFR1 promotes cell death whereas ligation 
of TNFR2 more typically induces cell cycle entry. Since 
the low rate of proliferation of RCCCD133+cells may be 
protecting them from chemotherapy, we have investigated 
the effects of TNFR2 on RCCCD133+cells and asked whether 
such pre-treatment would induce proliferation and thereby 
render them more susceptible to cell cycle-dependent 
chemotherapeutic drugs [38].
RESULTS
Enumeration and characterization of 
CD133+cells in NK and ccRCC
Immunostaining on sections of NK demonstrated 
rare interstitial CD133+cells (NKCD133+) (mean <3%) 
within the cortex, consistent with a previous report [10]. 
In comparison, sections of ccRCC contained a noticeably 
higher frequency of RCCCD133+cells (RCCCD133+), which 
increased further with tumor grade (Figure 1A panel 
i, quantified in B), ranging from mean ~6-8% in grade 
1/2 tumors to 14-16% in grade 3/4 tumors. Combined-
immunostaining for CD133 and a stem cell transcription 
factor, Oct4, demonstrated a strong nuclear staining of Oct4 
in 8% of NKCD133+ and 12% of RCCCD133+cells (Figure 1A, 
panel ii). Cultures of CD133+cells isolated from either NK 
and ccRCC demonstrated spindle-shaped morphology and 
scanty cytoplasm (Figure 1C). Because the glycosylated 
form of CD133 expression that is recognized appears to 
vary with the antibody used for staining [39] and because 
different glycosylation patterns may be indicative with 
stemness, we tested different antibodies on our isolated 
cell populations. Four different anti-CD133 monoclonal 
antibodies (W6B3C1, AC133, ab19898, E93002) displayed 
concordant immunolabeling (Supplementary Figure 1) and 
the same cells expressed a marked signal for stem cell-
associated markers [Oct4, Lin28, Nanog and Sox2) and for 
vimentin but lacked epithelial [cytokeratin and epithelial 
cell adhesion molecule (EpCAM)], endothelial [PECAM-1 
(CD31)] and leukocyte [leukocyte common antigen (CD45)] 
markers (Figure 1E). This phenotype is most consistent 
with but does not absolutely establish identity as a stem cell 
population.
Expression of TNF and TNFRs and responses to 
TNF by RCCCD133+ and NKCD133+cells
RCCCD133+cells were examined for protein expression 
of TNF and TNFRs at the basal level (untreated UT; 0h) and 
after treatment with wtTNF at various time points (3,6 & 
18h). TNF and TNFRs were negligible in UT cultures, with 
TNFR2 expression detected at 3, 6 and 18h, with a higher 
level of expression at 18h. In comparison, TNF and TNFR1 
expression were detected only in 18h cultures. (Figure 2A). 
Corresponding organ cultures of ccRCC demonstrated 
different levels of TNF (21+1.1%), TNFR1 (6.0+0.5%) and 
TNFR2 (28+1.2%) in CD133+cells. There were also a few 
CD133- cells within the interstitial tissue that were positive 
for TNF (25.0+0.2%), TNFR1 (2.0+0.1%) or TNFR2 
(18.0+0.5%) (Figure 2B). Treatment with wtTNF increased 
TNFR2 protein expression in both cultured cell types, but 
the effect was more pronounced in RCCCD133+cells with a 
higher expression detected at 18h (15.2+0.8%) compared to 
6h (8.1+0.4%) or 3h (6.0+0.5%). wtTNF also induced TNF 
(4.4+0.2%) and TNFR1 protein expression (3.0+0.1%) 
at 18h but not at 6 or 3h. Interestingly, R2TNF induced 
TNFR2 but not TNF or TNFR1 while R1TNF induced 
TNFR1 but not TNF or TNFR2 (data not shown). qRT-
PCR of similar cultures demonstrated induction of TNF 
mRNA expression by wtTNF; increases were noted but did 
not reach significance in NKCD133+cells treated with R1TNF 
or R2TNF compared to UT cultures (***p<0.0001). In 
comparison, all three treatments significantly induced TNF 
mRNA expression in RCCCD133+cells (***p<0.0001 vs UT). 
Notably, wtTNF and R1TNF (but not R2TNF) induced 
TNFR1 mRNA expression, with a more pronounced 
expression demonstrated in RCCCD133+cells and induced 
by wtTNF (***p<0.0001) than by R1TNF (┼p<0.05) vs UT 
cultures. TNFR2 mRNA expression was induced by wtTNF 
and R2TNF (not R1TNF) (***p<0.0001 vs UT cultures) 
with a higher level of expression in RCCCD133+ compared to 
NKCD133+cells (+p<0.05) (Figure 2C).
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We next assessed the effect of wtTNF, R1TNF 
and R2TNF on the induction of cell death and cell cycle 
activation in RCCCD133+ and NKCD133+cells. wtTNF or 
R1TNF each induced increased cell death in RCCCD133+cells 
as compared to UT or R2TNF-treated cultures [~27+0.9% 
by wtTNF and ~19+0.7% by R1TNF], positive for TUNEL 
in a time-dependent manner, with a marked increase in death 
in 18h cultures (Figure 3A and 3B and Supplementary Table 
1). These effects were less pronounced in NKCD133+cells, in 
which wtTNF induced ~12+0.2% and R1TNF-induced 
~6+0.2% cell death. Some RCCCD133+/TUNEL+ cells with 
fragmented nuclei were TNFR1+ (but not TNFR2+) with 
wtTNF inducing ~13+0.2% and R1TNF~6.6+0.2% (Figure 
3C and Supplementary Table 2). Because R1TNF-induction 
of cell death in RCC organ cultures has been positively 
correlated with caspase activation [37], we examined similar 
cultures positive for TUNEL and TNFR1 for expression of 
cleaved caspase-3Asp175 by immunofluorescence (IF) and 
Figure 1: A. Representative confocal image of ccRCC grade 3 show a significantly larger number of CD133+cells as compared to NK 
(arrows) (i), with some CD133+cells also positive for stem cell transcription factor Oct4 (arrows) (ii) B. The increase in CD133+cells 
correlate with tumor grade (*p<0.05 - grades 1 & 2 vs NK; ***p<0.001 - grades 3 & 4 vs NK), with more cells detected in grade 3/4 as 
compared to grade 1/2 (±p<0.01). C. Phase-contrast images of tissue-enriched CD133+cells from NK (NKCD133+) and RCC (RCCCD133+) 
show spindle-shaped morphology and a scanty cytoplasm and, D. are strongly positive for CD133. E. Both the cell types show expression 
of stem cell markers (Oct4, Lin28, Nanog and Sox2) and vimentin but lack epithelial, endothelial and leukocyte differentiation markers 
(Cytokeratin, EpCAM, CD31, CD45) t-tubules; G1-G4 - tumor grades 1- 4. Error bars represent mean ± SEM, data are from at least 3 
independent experiments with similar results.
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flow cytometry (FACS). 77% of the RCCCD133+cells treated 
with wtTNF that stained positive for TUNEL also stained 
positive for cleaved caspase 3Asp175 by FACS. However, 
only 14% of wtTNF-treated TUNEL positive NKCD133+cells 
stained positive for cleaved caspase 3Asp175 (Supplementary 
Figures 2A and 2B). These data suggest that the majority 
of TNF-induced cell death in RCCCD133+cells occurs via 
caspase-3 activation.
wtTNF and R2TNF (but not R1TNF) induced 
increased pH3S10 signal, a marker of cell proliferation, 
and this was more pronounced in RCCCD133+cells (wtTNF 
~17%, R2TNF ~13%) compared to NKCD133+cells (wtTNF 
Figure 2: A. CD133+ cells isolated from RCC (RCCCD133+) were quantified for expression of TNF or TNFR1 or TNFR2 at basal level (0h) 
and after treatment with wtTNF at various time points (3, 6 & 18h). TNFR2 expression is detected in cells at 3, 6 and 18h, with a higher 
level of expression after 18h. In comparison, expression for TNF and TNFR1 is only detected after 18h cultures. B. Representative images 
of corresponding ccRCC organ cultures show staining of TNF or TNFR1 or TNFR2 in CD133+cells (open arrows), with a few CD133-cells 
also positive for TNF or TNFR2 (shaded arrows). C. qRT-PCR analysis of RCCCD133+ and NKCD133+cells at day 7 following treatment with 
wtTNF, R1TNF and R2TNF show mRNA expression normalized to control samples value of 1 for each cell type. Error bars represent the 
mean ± SEM, ***p<0.0001 vs UT; **p<0.001 vs UT; +p<0.05 vs R2TNF; ┼p<0.05 vs R1TNF, ns-not significant analyzed by ANOVA and 
Bonferonni post hoc; of data from at least 3 independent experiments with similar results.
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~7%, R2TNF ~5%) (Figures 3D and 3E). Combined-
immunostaining for pH3S10 and TNFR2 demonstrated 
a strong signal for TNFR2 in some proliferating 
RCCCD133+cells (wtTNF~8% and R2TNF~6% vs 5% and 
3% in NKCD133+cells)(Figure 3F). To further confirm TNF-
induction of cell cycle entry, similarly treated cultures 
were subjected to IF with an alternative marker of cell 
proliferation, PCNA [40] (Figure 4A). FACS analysis of 
similar cultures for PCNA expression were concordant 
with IF findings with wtTNF and R2TNF (but not R1TNF) 
Figure 3: Representative confocal images of tissue-enriched CD133+cells from ccRCC and NK (RCCCD133+ and 
NKCD133+) immunostained for CD133 followed by TUNEL assay. A. Untreated (UT) and R2-TNF-treated cultures show a 
rare signal for TUNEL (arrows). In contrast, cultures treated with wtTNF and R1TNF show an increased number of TUNEL+nuclei 
(arrows). B. Quantification of RCCCD133+/TUNEL+ and NKCD133+/TUNEL+ in 10 random fields of view at x40 magnification show a time-
dependent increase in the number of positive cells, more pronounced in 18h than 3h cultures, with C. some RCCCD133+/TUNEL+cells are 
also positive for TNFR1 (red) D. RCCCD133+cells immunostained for pH3S10 (marker of cell cycle) show a rare pH3S10 positive nuclei in 
untreated (UT) and in R1TNF-treated cultures, while wtTNF and R2TNF-treated cultures show a strong signal (arrows). E. Percentage 
of RCCCD133+/pH3S10+cells in 10 random fields of view at x40 magnification, presented as proliferative index, show a time-dependent 
increase in proliferative cells, more pronounced in 18h cultures. F. Some proliferative RCCCD133+/pH3S10+cells are also positive for TNFR2 
(green) (shaded arrows) with a few non-poliferative cells (pH3S10-) positive for TNFR2 (open arrows). Nuclei stained with Hoechst-33342. 
Bars=mean + SEM, ***p<0.0001; **p<0.001 ; +p<0.05 signify statistically significant difference between treatments, data are from at least 3 
independent experiments with similar results, ns-not significant.
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showing a marked expression, more pronounced in 
RCCCD133+ compared to NKCD133+cells (Figure 4B). Similar 
effects of wtTNF and R2TNF were demonstrated by cell 
viability assays (Figures 4C and 4D) in a time-dependent 
manner with increase viability in cultures at day 4 vs day 2 
and in RCCCD133+ vs NKCD133+cells. These data are consistent 
with the interpretation that TNF induces cell death of 
CD133+ normal and malignant renal cells through TNFR1 
and cell cycle entry through TNFR2 in RCCCD133+cells. The 
ability of wtTNF but neither of the muteins to increase 
TNF staining is unexplained but all three treatments 
induced TNF mRNA in isolated RCCCD133+cells.
TNFR2 sensitizes RCCCD133+cells to killing by 
Cyclophosphamide (CP)
Having established that signling through TNFR2 
does promote entry of RCCCD133+ into cell cycle, we next 
sought to determine whether R2TNF sensitizes RCCCD133+ 
or NKCD133+cells to killing by CP. Cells were exposed to 
Figure 4: A. Representative confiocal images of combined staining for TNFR2 and proliferative nuclear antigen (PCNA) showing co-
staining in some RCCCD133+ cells (arrows). B. Representative flow cytometry analysis of similar cultures from ccRCC and NK (RCCCD133+ 
and NKCD133+) show a high expression of PCNA induced by wtTNF- or R2TNF-treatment as compared to R1-TNF-treated and control 
cultures (UT) after day 4. Quantification of two cell viability assays; CCK-8 C. and trypan blue exclusion assay D. are concordant with 
flow cytometry showing an increase cell viability in cultures treated with wtTNF- and R2TNF as compared to UT and R1TNF-treated 
cultures. Error bars represent the mean + SEM, ***p<0.0001 vs UT; **p<0.001 vs UT, ¥p<0.05 vs R1TNF; ±p<0.05 vs Day 2 (R2TNF), ns-not 
significant; data of at least 3 independent experiments with similar results.
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either CP alone, R2TNF alone, or CP followed by R2TNF 
(CP+R2TNF) or to R2TNF followed by CP (R2TNF+CP), 
and then analyzed by staining with FITC--conjugated 
Annexin-V/Propidium Iodide (PI)and examined by FACS. 
In comparison with UT cultures, R2TNF+CP (***p<0.001), 
CP alone and CP+R2TNF (*p<0.05) all induced some 
death in RCCCD133+cells with the highest level of cell death 
induced by R2TNF+CP compared to treatment with CP 
alone (+p<0.01) or CP+R2TNF (*p<0.01). R2TNF+CP also 
resulted in death of NKCD133+ but a significant level of death 
was observed in only 1 out of 3 experiments, indicating 
that RCCCD133+cells are more sensitive to the cytotoxic 
effects of CP than are NKCD133+ (Figure 5). The percentage 
of dead RCCCD133+ and NKCD133+cells is presented in 
Supplementary Table 3. Moreover, representative images of 
FITC-Annexin-V/PI and phase-contrast microscopy are shown 
in Supplementary Figures 3A and 3B. These data indicate 
that signaling through TNFR2, probably by inducing 
proliferation, sensitizes RCCCD133+cells to killing by CP.
DISCUSSION
Our rationale for studying CD133+cells in NK 
or RCC is their potential role as renal stem cell and 
tumor stem cells, respectively. In the present paper, we 
characterized these populations both in intact tissue and in 
cell culture. We have evaluated their responses to TNF, as 
this cytokine appears to play a complex role both in NK 
and ccRCC, being capable of inducing both proliferation 
and cytotoxic responses [37]. Analyzing responses 
mediated by TNFR1 and TNFR2 using muteins that 
selectively activate one receptor or the other can separate 
some of the seeming contradictions in TNF responses. 
Our key findings are that in intact renal tissue there is 
a significant increase in the numbers of CD133+cells 
in RCC vs NK, consistent with a prior report [27]. 
Furthermore, the frequency of RCCCD133+cells increased 
with higher tumor grade. Both NKCD133+ and RCCCD133+cells 
are responsive to TNF. Specifically, ligation of TNFR2 
Figure 5: Flow cytometry analysis showing the effect of cyclophosphamide (CP) in cultures of tissue-enriched 
CD133+cells from ccRCC and NK (RCCCD133+ and NKCD133+) treated with R2TNF before and after CP or with CP alone. 
Quantification of average percentage of dead cells stained with Annexin V and Propidium Iodide and analyzed with flow cytometry show 
a strong staining for both stains in RCCCD133+ treated with R2TNF for 48h prior to treatment with CP (1.25μM) (R2TNF+CP) for a further 
48h compared to untreated controls (UT) (***p<0.0001) or cultures treated with CP alone (**p<0.001) or CP+R2TNF (*p<0.01). A significant 
increase in both staining was demonstrated in cultures exposed to CP alone vs UT or vs R2TNF alone (+p<0.05) but not vs CP+R2TNF. 
R2TNF+CP also induced death in NKCD133+ but only in 1 out of 3 experiments resulting in a no significant effect. Errors bars mean + SEM, 
data of least 3 independent experiments with similar results.
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increases transcription of TNFR2 and promotes their entry 
into cell cycle in organ culture. The entry of RCCCD133+cells 
into cell cycle in response to TNFR2 signaling increased 
susceptibility to CP-induced cell death. R2TNF also 
induced proliferation of NKCD133+cells but CP was less 
effective in killing them as compared to RCCCD133+cells.
A key question, not fully answered by our findings, 
is whether the interstitial CD133+cells in the renal cortex 
are or are not renal stem cells. We found that CD133+cells 
in RCC and NK were uniformly negative for the 
hematopoietic stem cell markers CD31 or CD45 but were 
strongly and persistently positive for stem cell markers 
(Oct4, Sox2, Nanog and Lin28) and for vimentin [41]. 
These data strongly suggest that they are a primitive cell 
type, consistent with previous studies [27, 29]. Although, 
we failed to detect cytokeratin in the CD133+ cells from 
both the study groups, we did however, observe its 
expression when driven to differentiate into an epithelial 
lineage (RA-L unpublished data), suggesting capacity of 
these progenitor cells to acquire markers characteristic of 
fully differentiated renal epithelia. Stem cell transcription 
factors Oct4 and/or Sox2 have been found to bind to the 
P1 promoter region of the CD133 gene and ectopic Oct4 or 
Sox2 expression has been shown to trigger the CD133P1 
activity in the lung cancer cell lines [42]. CD133 marker 
was initially used to identify cancer stem cells (CSCs) in 
brain tumor [18, 19]. CD133+stem/progenitor cells, also 
referred to as tumor-initiating cells, CSCs, stem-like cells 
[9, 20, 23, 29, 30, 43-47], have been isolated in normal and 
neoplastic tissue including the human kidney and RCC [9-
11, 27, 29, 45, 48, 49]. Although some CD133+cells have 
been shown to possess self-renewal properties and clonal 
efficiency; current literature on the use of CD133 as the 
only marker to identify stem cells has been questioned 
since its presence has been localized in a variety of adult 
epithelial cells including pancreas, liver and renal tubules 
[10, 26, 28, 50, 51] and localize to membrane protrusions 
[6]. In RCC, CD133+cells have been detected in apical 
membrane of tumor cells in macro/microcytic regions [27] 
and in perinecrotic/ perivascular areas [20]. Moreover, in 
human kidneys, CD133 immunoreactivity was localized 
to proximal tubules and Bowman’s capsule [50] and not 
restricted to stem cells. Interestingly, other groups have 
shown that CD133 is not only a biomarker, but also 
functions in cell growth, development and tumor biology 
[52]. Indeed, CD133 expression and post-translational 
modification are dynamic and reversible that is dependent 
on cell microenvironment and physiological regulation 
[53].
The tumorigenic potential of CD133+cells 
depends on the tissue of origin. For example, in human 
brain, CD133+cells are capable of self-renewal and 
recapitulate the original tumor when transplanted in 
SCID mice [19]. Similarly, CD133+cells from primary 
lung tumors show higher tumorigenic potential than 
their CD133−counterparts and are able to reproduce the 
original tumor in SCID mice [8]. Conversely, in RCC, 
undifferentiated CD133+cells express low level of Oct4, 
have a low proliferative rate [27] and fail to form tumors 
independently in SCID mice but support tumor growth 
when co-transplanted with tumor cells [29]. These 
reports indicate that CD133+cells are a heterogeneous cell 
population with varied function(s).
Recruitment of CD133+ pro-angiogenic cells in 
cancer has been considered to play an important role in 
resistance to vascular growth factor (VEGF) neutralizing 
antibody such as bevacizumab, possibly due to failure 
to inhibit their differentiation into endothelial cell types 
[54]. Moreover, CD133 gene polymorphism have been 
associated with lower overall survival rate in patients 
treated with bevacizumab in metastatic colorectal cancer 
treated [55]. These studies generally have as their premise 
that VEGF as a tumor angiogenic factor. Neutralization of 
VEGF may play an additional role in RCC as these cells, 
like endothelium, express VEGF receptor 2 (VEGFR2) 
and proliferate in response to its autocrine production. Our 
prior studies of malignant tubular epithelial cells in ccRCC 
organ culture indicated that signalling through TNFR2 
induced ligand-independent transactivation of VEGFR2 
and that blockade of VEGFR2 kinase activity inhibited 
TNFR2-induced cell cycle entry [37, 56, 57].
Tumor cells and tumor microenvironment may 
play a vital role in regulating self-renewal properties of 
CD133+cells in RCC [29]. Inflammation and hypoxia are 
characteristic features of neoplasm and facilitates tumor 
growth. Cancer-associated inflammation is characterized 
by expression of cytokines, influx of leukocytes, tissue 
remodeling and angiogenesis [58–60]. Cytokines have 
pro-tumor properties. TNF is secreted by RCC [37, 
61], and increase stemness properties in RCC in 2D 
cultures [62]. TNF targets the quiescent/slow-cycling 
stem cells and promotes PI3K/AKT-driven expansion 
in melanoma by preventing their asymmetrical self-
renewal [63]. These data strongly suggest that TNF, 
present in the tumor microenvironment, may influence 
the behaviour of CD133+cells in RCC and potentiate 
their self-renewal properties. In our preliminary studies, 
we have demonstrated TNF-induced upregulation of 
stem cell transcription genes (Oct4, Nanog and Lin28) in 
RCCCD133+cells (RA-L, unpublished data), consistent with a 
prior report by Ueda et al [64]. Hypoxia has been shown to 
influence the expression of CD133 in RCC [65], as well as 
in lung cancer, pancreatic cancer and glioma cells [66, 67]. 
We have previously reported that hypoxia both increases 
TNF expression and TNFR2 induction and expression 
of a stem cell marker Lin28 in c-kit+ cardiac stem cells 
that then enter cell cycle [68]. Collectively, these findings 
suggest that a transient exposure of RCCCD133+cells to TNF 
and/or hypoxia may imprint their long-lasting molecular 
and/or cellular changes with functional consequences.
In summary, our data confirm that CD133+cells are 
present in larger numbers in ccRCC than in NK and that 
they respond to TNFR2 signaling, which promotes their 
proliferation. While the specific role of RCCCD133+cells 
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in renal tumours remain unclear, they likely have 
pathogenetic signficance. TNF, signaling via TNFR2, not 
only causes these cells to proliferate, it also increases their 
senstivity to cell cycle-sensitive chemotherapy. Therefore, 
priming these cells with a TNFR2 agonist may enhance 
the efficacy of chemotherapy for ccRCC.
MATERIALS AND METHODS
Antibodies, cytokines, and reagents
Recombinant human TNF (cat~201-TA), mouse 
anti-TNFR1 (cat~MAB225) and mouse anti-TNFR2 
(MAB226) all from R&D Systems, Abington, UK, 
rabbit anti-TNFR1 (cat~ab19139) (Abcam, Cambridge, 
UK), rabbit anti-TNFR2 (cat~sc-7862 H202, Santa 
Cruz Biotechnology, Heidelberg, Germany), mouse 
anti-PECAM/CD31 (cat~M0823), mouse anti-
cytokeratin (cat~M0821 clone MNF116) and mouse 
anti-CD45 (cat~M0701), mouse anti-Vimentin Clone V9 
(cat~M0725) all from Dakocytomation, Ely, UK, rabbit 
anti-Vimentin (D21H3)(Cell Signaling Technology Inc, 
UK), rabbit anti-CD133 (E90032, Source Bioscience, 
Nottingham, UK); rabbit anti-CD133 (cat~ab19898, 
Abcam), mouse anti-CD133/1-W6B3C1 (cat~130-
092-395) and mouse anti-CD133/1-AC133 (cat~130-
090-422) both from Miltenyi Biotec Ltd, Surrey, UK, 
rabbit anti-human EpCAM (GTX113091, Source 
Bioscience); mouse anti-Sox2 (cat~MCA5660T) 
and mouse anti-Nanog (cat~MCA5657T, Bio-Rad 
Laboratories Ltd , Hertfordshire, UK), Hoechst-33342 
(Thermo Fisher Scientific, Paisley, UK); rabbit anti-
Lin28 (cat~ab46020), rabbit anti-Oct4 (cat~ab19857), 
mouse anti-phosphorylated Histone H3S10 (pH3S10)
(cat~ab14955), rabbit anti-phosphorylated Histone H3S10 
(pH3S10)(cat~ab5176), anti-TNF-alpha (cat~ab6671) 
all from Abcam, mouse anti-proliferative cell nuclear 
antigen (PCNA, cat~MAB424 clone PC10, Millipore, 
Hertfordshire, UK). Cleaved caspase-3Asp175 (cat~9661, 
Cell Signaling Technology, Leiden, The Netherlands). 
Tissue Dissociation Kit (cat~130-095-929), MS 
columns (cat~130-042-201), C-Tubes (cat~130-093-
237) were from Miltenyi Biotec. TUNEL label (dUTP-
FITC) (cat~11767291910), Terminal transferase enzyme 
(TdT) (cat~03333566001), deoxynuclease-1 (DNase-1) 
and Annexin-V-FLUOS Staining Kit all from Roche 
Diagnostics, Mannheim, Germany. Recombinant 
mutations of the TNF sequence which enable the mutated 
protein (“mutein”) to bind selectively to either of the 
TNFR subtypes; TNFR1 (R1TNF) and TNFR2 (R2TNF) 
[37, 40, 69]. Cyclophosphamide was from Sigma-Aldrich, 
St. Louis, MO.
Tissue collection
Experiments using human tissue were performed 
with informed consent of patients and approval of 
the local ethics committee and Cambridge University 
hospital Tissue Bank. RCC tissue obtained from radical 
nephrectomy specimens was immediately excised from 
tumors that grossly appeared to be ccRCC. This tumor 
classification was later verified by routine histological 
assessment of paraffin-wax embedded samples. Non-clear 
cell histological tumor types (e.g. papillary, chromophobe, 
and collecting duct) [70] were excluded and only ccRCC, 
graded according to the four-tiered Fuhrman nuclear 
grading system [71] and pathologically staged based on 
the TNM classification [37, 72] were used. Tissue samples 
from 40 patients were collected and scored as Fuhrman 
grade 1 (n=10), Fuhrman grade 2 (n=10), Fuhrman grade 
3 (n=12), and Fuhrman grade 4 (n=8). In parallel, adjacent 
non-tumor kidney (NK) (n=20), categorized histologically 
as normal kidney cortex was collected remote from the 
tumor site. All samples were either fixed overnight at 4°C 
in 4% formaldehyde in 0.1M phosphate buffer pH 7.6 and 
paraffin wax-embedded for immunofluorescence or snap-
frozen in isopentene-cooled in liquid nitrogen. Parallel-
unfixed fresh samples were processed for organ culture 
experiments.
Kidney organ cultures
Organ cultures were performed as previously 
described [37]. In brief, duplicate 1 mm3 fragments of 
tissue from ccRCC grade 1 and NK (n=5 per study group) 
were immersed in M199 medium containing 10% heat-
inactivated fetal calf serum (FCS), antibiotics and 2.2mM 
glutamine. Cultures were either left in media alone 
(untreated controls; UT) or treated with TNF (10ng/mL) or 
R1TNF or R2TNF (1µg/mL) [37, 40, 73] at various time 
points (0, 3, 6 and 18h). Cultures were harvested, fixed in 
4% formaldehyde and embedded in paraffin-wax.
Processing, isolation, and culture of 
CD133+cells from ccRCC and nontumor 
adjacent kidney (NK)
ccRCC and NK (n=10 per study group) were 
enzymatically digested as previously reported [68]. In 
brief, tissue was digested into single cell suspension using 
Tissue Dissociation Kit on a GentleMACs Disassociator 
and incubated on a MACsMix rotator (Miltenyi) for 
30 min at 37oC, centrifuged at 300g for 5 min, passed 
through 40µm strainer to remove cell clumps. Single cell 
suspensions were cultured in nondifferentiating expansion 
medium [29] [containing 60% low-glucose Dulbecco’s 
modified Eagle’s medium-LG (DMEM-LG), 2% FCS, 
40% MCDB-201, 1x insulin-transferrin-selenium, 1x 
linoleic acid 2-phosphate, 10-9 M dexamathasone, 104M 
ascorbic acid 2-phosphate, 10 ng/mL epidermal growth 
factor (EFG), 10 ng/mL platelet derived growth factor, 
and 1000 units/mL lymphocyte inhibitory factor, 100U 
penicillin, 1000U streptomycin] all from Invitrogen, 
Paisley, United Kingdom. Enrichment of CD133+cells 
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from ccRCC and NK (referred to as RCCCD133+ and 
NKCD133+) was achieved by magnetic cell sorting system 
according to the manufacturer's instructions (Mitenyi). 
A total of 6 x108 cells were magnetically labeled with 
CD133 microbeads and passed through the MACS column 
on MiniMACS Separator. The magnetically labeled 
CD133+cells were eluted from magnetic column as the 
positively selected cell fraction. Enriched population 
of RCCCD133+ and NKCD133+cells (~6x105 cells/mL) were 
seeded in T25 flasks and transferred to eight-well glass 
slide chambers (Thermo-scientific, UK). Once confluent, 
cells were either UT or treated with wtTNF or R1TNF or 
R2TNF for 3 and 18h.
Single and combined immunofluorescence (IF)
Sections of ccRCC, NK and corresponding organ 
cultures were immunostained for CD31 (1:50 dilution) as 
previously described [37, 40]. As CD133 expression has 
been associated with stem/progenitor cells in RCC, we 
co-immunostained some cultures with anti-CD133 and a 
panel of stemness markers (Lin28, Oct4, Nanog, Sox2) 
or markers for epithelial, endothelial and leukocytes 
(cytokeratin, CD31, EpCAM, CD45) and a mesenchymal 
marker (vimentin) (all used at 1:100 dilution). pH3S10 and 
PCNA (used at 1:500 and 1:200 dilution) were used to 
detect cell cycle activation and assessed in association with 
TNF and TNFRs. In addition, some cultures were subjected 
to co-immunostaining for TNFR1 and cleaved caspase-
3Asp175. Antibody binding sites were detected with Northern 
Light-498 or -557-conjugated secondary antibodies (diluted 
1:100), incubated 1h at room temperature. Hoechst-33342 
(1μg/ml) was used for nuclei detection. Species-specific 
antiseras were used as negative controls. Slides were 
viewed on a Leica TCS-SPE confocal microscopy (CLSM) 
(Leica Microsystems, Milton Keynes, UK) and image 
for each fluorophore was acquired sequentially using the 
same constant acquisition time and settings rather than 
simultaneously to avoid crosstalk between channels. Images 
were then processed in Adobe Photoshop CS6 software.
Determination of RCCCD133+ and NKCD133+ cell 
death
The effect of wtTNF, R1TNF and R2TNF treatment 
on cell death in RCCCD133+ and NKCD133+ was assessed 
using TUNEL as previously described [37, 40, 74]. 
Briefly, RCCCD133+ and NKCD133 cells and organ cultures 
from each of the four treatments were incubated with 
FITC-dUTP-TUNEL label mix containing TdT-enzyme 
plus Hoechst-33342 for nuclei detection and mounted in 
Vectorshield mountant (Vector Laboratories, Peterborough, 
UK). For negative controls, TdT-enzyme was omitted 
and for positive controls cultures were pretreated with 
DNase-1 enzyme (Promega, Hampshire, UK) before 
TUNEL. Three experiments were performed separately. 
Following TUNEL, some cultures were incubated with 
anti-TNF and anti-TNFRs antibodies and detected using 
Northern Lights568-conjugated secondary antibody plus 
Hoechst-33342. In addition, cell suspensions from UT 
and wtTNF-treated cultures from both the study groups 
were labeled with an antibody to cleaved-caspase-3Asp175 
followed by incubation with a FITC-conjugated secondary 
antibody and analyzed by flow cytometry (FACS) using 
Canto II (BD Biosciences). All slides were viewed on a 
CLSM.
RNA isolation and quantitative reverse-
transcription polymerase chain reaction (qRT-
PCR)
Total cellular RNA was extracted from UT and 
wtTNF-, R1TNF-, R2TNF-treated cultures of RCCCD133+ 
and NKCD133+cells using the RNeasy Plus Mini Kit 
(Qiagen, Germany). 6µg RNA from each sample was 
reversely transcribed into cDNA and measured using 
Taqman Reverse Transcription Kit according to the 
manufacturer's instructions (ABI7700 System, Applied 
Biosystems, CA, USA). TaqMan_Gene Expression Assay 
ID: TNFR1 (Hs00533560), TNFR2 (Hs00153550), TNF 
(Hs99999043) were used. (GAPDH; Hs04420697) was 
used for normalization.
Determination of RCCCD133+ and NKCD133+ cell 
proliferation
The effect of wtTNF, R1TNF and R2TNF 
on cell proliferation was evaluated by FACS using 
immunostaining for anti-PCNA antibody and two 
different cell viability assays [cell counting kit-8 (CCK-8) 
and trypan blue exclusion]. RCCCD133+ and NKCD133+cells 
serum-depleted were seeded in 12-well culture plates for 
FACS (1x105cells/mL), for CCK-8 assay (3x104cells/mL) 
and for trypan blue staining (5×103cells/mL) in 24-well 
culture plates. Cultures were either left UT or treated with 
wtTNF, R1TNF or R2TNF for 48h and 96h. Cells were 
then rinsed in PBS, blocked with FcR blocking reagent 
(Miltenyi) and incubated with PE-conjugated antibody to 
PCNA- or with PE-conjugated isotype-specific antisera 
before examining using FACS Canto II. 10,000 events 
were collected per sample and the data analysed with 
FlowJo software. For the CCK-8, cells were treated for 
48h and the WST-8 reagent (10μL/well) Sigma-Aldrich, 
UK was added to each well and incubated for 2h at 37°C. 
The absorbance optical density (OD) (proportional to the 
relative abundance of living cells) was measured at 450nm 
wavelength using a microplate reader (Bio-Rad, USA). For 
trypan blue exclusion assay, 200µl cells were incubated in 
0.4% (w/v) trypan blue solution containing 0.81% NaCl 
plus 0.06% (w/v) dibasic potassium phosphate for 3 min 
at room temperature and counted using a haemocytometer. 
Viable and non-viable cells were recorded separately, and 
the means of 3 independent cell counts from 3 separate 
experiments were pooled for analysis.
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Determination of cytotoxic effect of 
cyclophosphamide (CP) by FACS
To evaluate the effect of CP following cell cycle 
activation of RCCCD133+ and NKCD133+cells by R2TNF, cells 
(0.5×105cells/well) were seeded in 24-well plates coated 
with human plasma fibronectin. Cells were then either left 
UT or treated with CP alone or R2TNF alone, or R2TNF for 
48h before CP (R2TNF+CP) (to induce cell proliferation) or 
after (CP+R2TNF) for a further 48h. A dose response curve 
was initially set up to determine the optimal effect of CP 
using documented concentrations (1.25, 2.5 and 5µM) [75, 
76] at 24h and 48h time points. No significant difference in 
toxicity was demonstrated between the 3 doses, although a 
higher number of dead cells were evident at 48h. 1.25µM CP 
for 48h was therefore used for all subsequent experiments. 
Following treatment, cells were harvested and cytotoxic 
effect of CP determined by Annexin V/Propidium Iodide 
(PI) staining using FACS. Cells were gated as fractions of 
non-apoptotic live cells (Annexin V-/PI-), early apoptotic 
cells (Annexin V+/PI-), late apoptotic and necrotic cells 
(Annexin V+/PI+) and calculated as the average percentage 
of dead cells. FlowJo and GraphPad softwares were used to 
analyze the data, represented as mean ± SEM from at least 
3 independent experiments.
Data analysis
Cell death and proliferative indices
The average number of RCCCD133+ and NKCD133+cells 
positive for TUNEL were counted in 10 random fields of 
view at x40 magnification from each treatment divided 
by the total cell numbers to generate the percentage 
of positive cells. Similarly, the numbers of RCCCD133+ 
and NKCD133+cells positive for pH3S10 were counted and 
divided by the total cell numbers to generate the % of 
positive cells, calculated as proliferative index (PI) for 
each treatment. Error bars represent mean ± SEM. Each 
experiment was repeated at least 3 times and the same 
statistically significant differences between experimental 
groups were observed in all three independent experiments 
although the absolute values varied. Microsoft Excel 
2013 and GraphPad Prism 5.02 softwares were used for 
data processing. Statistical significance was assessed by 
the analysis of variance test and a p-value of <0.05 were 
considered significant.
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